Castle Biosciences, Inc. (CSTL)
$32.76-4.82%Close
SELLRECOVERY · day 87
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $994M
- Beta
- 0.94
- P/E (TTM)
- -50.58
- Short % float
- 7.46%
- Days to cover
- 4.8
- SI change
- +5.3%
- 1W
- -10.61%
- 1M
- +1.33%
- vs SPY 1W
- -11.04%
- vs SPY 1M
- -0.73%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 26
- VALUE
- 14
- GROWTH
- 52
- GARP
- 11
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-2.5%
REV YoY-
ROE-4.2%
EPS YoY-
ROA-3.5%
GROSS77
OP-9
NET-5
[VALUATION]
P/E TTM-50.58
P/E FWD-
SECTOR PE20.54
INDUSTRY PE31.57
P/B2.16
P/FCF-
EV/EBITDA-307.07
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E7.80
ALTMAN Z-
CURR RATIO6.04
ND/EBITDA-
BETA0.94
Company news
FAQ
- What is LOPJLB’s current signal on CSTL?
- LOPJLB’s latest quantitative signal on Castle Biosciences, Inc. (CSTL) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is CSTL in?
- Castle Biosciences, Inc. (CSTL) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Castle Biosciences, Inc. (CSTL) do?
- Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in pati…